medvisМедицинская визуализацияMedical Visualization1607-07632408-9516RDS-Media Ltd.10.24835/1607-0763-2019-2-90-99medvis-775Research ArticleМАЛЫЙ ТАЗSMALL PELVISСистемы стандартизации оценки изображений при гибридной ПЭТ-визуализации рака предстательной железы с радиомечеными лигандами к простатспецифическому мембранному антигену: сравнительный обзор PROMISE и PSMA-RADS версии 1.0Imaging standardization systems for hybrid PET imaging of prostate cancer with radiolabeled prostate-specific membrane antigen ligands: comparative review of PROMISE and PSMA-RADS version 1.0ЛеонтьевА. В.LeontyevA. V.

Леонтьев Алексей Викторович – канд. мед. наук, заведующий отделением радионуклидной диагностики

125284 Москва, 2-й Боткинский проезд, д. 3. Тел.: +7-495-9458718

Alexey V. Leontyev – cand. of med. sci., Head of Nuclear Medicine Department 

125284 Moscow, Russia, 2th Botkinskij proezd, 3. Phone: +7-495-9458718

aleksleont@yandex.ruРубцоваН. А.RubtsovaN. A.

Рубцова Наталья Алефтиновна – доктор мед. наук, руководитель отдела лучевой диагностики

Natalia A. Rubtsova – doct. of med. sci., Head of Radiology Department

ХалимонА. И.KhalimonA. I.

Халимон Александр Игоревич – врач-рентгенолог отделения КТ и МРТ

Alexander I. Khalimon – radiologist of CT and MRI Department

КулиевМ. Т.KulievM. T.

Кулиев Магомед Темирланович – клинический ординатор кафедры онкологии, радиотерапии и пластической хирургии лечебного факультета на базе отделения радионуклидной диагностики

Magomed T. Kuliev – Resident of Oncology, Radiotherapy and Plastic Surgery Department

based at the Nuclear Medicine Department 

ПыловаИ. В.PylovaI. V.

Пылова Ирина Валентиновна – канд. мед. наук, врач-радиолог отделения радионуклидной диагностики

Irina V. Pylova – cand. of med. sci., nuclear medicine physician of Nuclear Medicine Department

ЛазутинаТ. Н.LazutinaT. N.

Лазутина Татьяна Николаевна – канд. мед. наук, врач-радиолог отделения радионуклидной диагностики

Tatyana N. Lazutina – cand. of med. sci., nuclear medicine physician of Nuclear Medicine Department

ХамадееваГ. Ф.KhamadeevaG. F.

Хамадеева Гульнара Фаридовна – клинический ординатор отделения радионуклидной диагностики

Gulnara F. Khamadeeva – Resident of Nuclear Medicine Department

КапринА. Д.KaprinA. D.

Каприн Андрей Дмитриевич – академик РАН, член-корр. РАО, доктор мед. наук, профессор, главный уролог РАН, заслуженный врач РФ, генеральный директор

заведующий кафедрой урологии и оперативной нефрологии с курсом онкоурологии медицинского факультета медицинского института 

Andrey D. Kaprin – Full Member of the Russian Academy of Sciences, Corresponding member of Russian Academy of Education, doct. of med. sci., Professor, Honored Doctor of the Russian Federation, Chief urologist of the Russian Academy of Sciences, General Director of 

Head of Department of urology and surgical nephrology with a course of oncourology at the medical faculty of medical 

МНИОИ имени П.А. Герцена – филиал ФГБУ “НМИЦ радиологии” Минздрава РоссииРоссияMoscow Research Oncology Institute named after P.A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian FederationRussian FederationФГАОУ ВО Первый МГМУ имени И.М. Сеченова (Сеченовский Университет); МНИОИ имени П.А. Герцена – филиал ФГБУ “НМИЦ радиологии” Минздрава РоссииРоссияFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Moscow Research Oncology Institute named after P.A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian FederationRussian FederationФГБУ “НМИЦ радиологии” Минздрава России; ФГАОУ ВО “Российский университет дружбы народов”Россия“National Medical Radiological Research Center” of the Ministry of Health of the Russian Federation; Institute of The Peoples' Friendship University of RussiaRussian Federation201916072019029099Copyright © Леонтьев А.В., Рубцова Н.А., Халимон А.И., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Хамадеева Г.Ф., Каприн А.Д., 20192019Леонтьев А.В., Рубцова Н.А., Халимон А.И., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Хамадеева Г.Ф., Каприн А.Д.Leontyev A.V., Rubtsova N.A., Khalimon A.I., Kuliev M.T., Pylova I.V., Lazutina T.N., Khamadeeva G.F., Kaprin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medvis.rdsmedia.ru/jour/article/view/775

В настоящей статье приведен сравнительный обзор двух систем для стандартизованной оценки результатов гибридной ПЭТ-визуализации с радиомечеными лигандами к ПСМА – PROMISE и PSMA-RADS версии 1.0. Подробно рассмотрены принципы классификации, номенклатура и алгоритмы оценки изображений с помощью данных систем, а также рекомендации по структурированию протокола исследования и заклю чения, освещены преимущества и недостатки предложенных систем.

This article provides a comparative review of two systems for standardized evaluation of the results of hybrid PET imaging with radiolabeled PSMA ligands – PROMISE and PSMA-RADS version 1.0. The principles of classification, nomenclature and evaluation algorithms, as well as recommendations for structuring research and conclusion protocols, highlighting the advantages and disadvantages of the proposed systems, are considered in detail.

рак предстательной железыРПЖПЭТ/КТПЭТ/МРТпростатспецифический мембранный антигенрадиофармпрепаратылиганды к ПСМАPROMISEPSMA-RADSprostate cancerbiochemical recurrencePET/CTPET/MRIprostate-specific membrane antigenradiopharmaceuticalsPSMA ligandsPROMISEPSMARADSReferencesOrel S.G., Kay N., Reynolds C., Sullivan D.C. BI-RADS categorization as a predictor of malignancy. Radiology. 1999; 221 (3): 845–850. http://doi.org/10.1148/radiology.211.3.r99jn31845. 2. Weinreb J.C., Barentsz J.O., Choyke P.L., Cornud F., Haider M.A., Macura K.J., Margolis D., Schnall M.D., Shtern F., Tempany C.M., Thoeny H.C., Verma S. PIRADS Prostate ImagingReporting and Data System: 2015, VersionOrel S.G., Kay N., Reynolds C., Sullivan D.C. BI-RADS categorization as a predictor of malignancy. Radiology. 1999; 221 (3): 845–850. http://doi.org/10.1148/radiology.211.3.r99jn31845. 2. Weinreb J.C., Barentsz J.O., Choyke P.L., Cornud F., Haider M.A., Macura K.J., Margolis D., Schnall M.D., Shtern F., Tempany C.M., Thoeny H.C., Verma S. PIRADS Prostate ImagingReporting and Data System: 2015, VersionEur. Urol. 2016; 69 (1): 16–40. http://doi.org/10.1016/j.eururo.2015.08.052.Eur. Urol. 2016; 69 (1): 16–40. http://doi.org/10.1016/j.eururo.2015.08.052.McKee B.J., Regis S.M., McKee A.B., Flacke S., Wald C. Performance of ACR LungRADS in a clinical CT lung screening program. J. Am. Coll. Radiol. 2015; 12 (3): 273–276. DOI: 10.1016/j.jacr.2014.08.004McKee B.J., Regis S.M., McKee A.B., Flacke S., Wald C. Performance of ACR LungRADS in a clinical CT lung screening program. J. Am. Coll. Radiol. 2015; 12 (3): 273–276. DOI: 10.1016/j.jacr.2014.08.004Purysko A.S., Remer E.M., Coppa C.P., Leão Filho H.M., Thupili C.R., Veniero J.C. LIRADS: a casebased review of the new categorization of liver findings in patients with endstage liver disease. Radiographics. 2012; 32 (7): 1977–1995. http://doi.org/10.1148/rg.327125026.Purysko A.S., Remer E.M., Coppa C.P., Leão Filho H.M., Thupili C.R., Veniero J.C. LIRADS: a casebased review of the new categorization of liver findings in patients with endstage liver disease. Radiographics. 2012; 32 (7): 1977–1995. http://doi.org/10.1148/rg.327125026.Tessler F.N., Middleton W.D., Grant E.G., Hoang J.K., Berland L.L., Teefey S.A., Cronan J.J., Beland M.D., Desser T.S., Frates M.C., Hammers L.W., Hamper U.M., Langer J.E., Reading C.C., Scoutt L.M., Stavros A.T. ACR thyroid imaging, reporting and data system (TIRADS): white Paper of the ACR TIRADS committee. J. Am. Coll. Radiol. 2017; 14 (5): 587–595. http://doi.org/10.1016/j.jacr.2017.01.046.Tessler F.N., Middleton W.D., Grant E.G., Hoang J.K., Berland L.L., Teefey S.A., Cronan J.J., Beland M.D., Desser T.S., Frates M.C., Hammers L.W., Hamper U.M., Langer J.E., Reading C.C., Scoutt L.M., Stavros A.T. ACR thyroid imaging, reporting and data system (TIRADS): white Paper of the ACR TIRADS committee. J. Am. Coll. Radiol. 2017; 14 (5): 587–595. http://doi.org/10.1016/j.jacr.2017.01.046.Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., Pruim J., Price P. Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer. 1999; 35 (13): 1773–1782.Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., Pruim J., Price P. Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer. 1999; 35 (13): 1773–1782.Wahl R., Jacene H., Kasamon Y., Lodge M. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50 (1): 122–150. http://doi.org/10.2967/jnumed.108.057307.Wahl R., Jacene H., Kasamon Y., Lodge M. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50 (1): 122–150. http://doi.org/10.2967/jnumed.108.057307.Cheson B., Fisher R., Barrington S. et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and nonhodgkin lymphoma: the lugano classification. J. Clin. Oncol. 2014; 32 (27): 3059–3067. http://doi.org/10.1200/JCO.2013.54.8800.Cheson B., Fisher R., Barrington S. et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and nonhodgkin lymphoma: the lugano classification. J. Clin. Oncol. 2014; 32 (27): 3059–3067. http://doi.org/10.1200/JCO.2013.54.8800.Marcus Ch., Tahari A., Ciarallo A., Wahl R., Subramaniam R. Head and neck PET/CT: therapy response interpretation criteria (‘Hopkins criteria’). J. Nucl. Med. 2014; 55 (1): 344.Marcus Ch., Tahari A., Ciarallo A., Wahl R., Subramaniam R. Head and neck PET/CT: therapy response interpretation criteria (‘Hopkins criteria’). J. Nucl. Med. 2014; 55 (1): 344.Rowe S., Pienta K., Pomper M., Gorin M. Structured Reporting System for ProstateSpecific Membrane Antigen-Targeted PET Imaging: PSMARADS Version 1.0. J. Nucl. Med. 2018; 59(3): 479–485. http://doi.org/10.2967/jnumed.117.195255.Rowe S., Pienta K., Pomper M., Gorin M. Structured Reporting System for ProstateSpecific Membrane Antigen-Targeted PET Imaging: PSMARADS Version 1.0. J. Nucl. Med. 2018; 59(3): 479–485. http://doi.org/10.2967/jnumed.117.195255.Eiber M., Herrmann K., Calais J., Hadaschik B., Giesel F.L., Hartenbach M., Hope T., Reiter R., Maurer T., Weber W.A., Fendler W.P. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMALigand PET/CT. J. Nucl. Med. 2018; 59 (3): 469–478. http://doi.org/10.2967/jnumed.117.198119.Eiber M., Herrmann K., Calais J., Hadaschik B., Giesel F.L., Hartenbach M., Hope T., Reiter R., Maurer T., Weber W.A., Fendler W.P. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMALigand PET/CT. J. Nucl. Med. 2018; 59 (3): 469–478. http://doi.org/10.2967/jnumed.117.198119.

The authors declare that there are no conflicts of interest present.